# Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

Last Update: Jan 14, 2025

This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.

ClinicalTrials.gov Identifier:
NCT06157086

Novartis Reference Number:COMB157GFR06

See if you Pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol. This is a non-interventional, prospective (primary data), multicenter study conducted in metropolitan France. The primary objective of this study is to describe the quality of life of MS patients after initiation of treatment with ofatumumab.

In order to form a representative sample of MS patients taking into account the terms of care in France, free or practicing neurologists in healthcare institutions (public or private) in different regions of France will be selected to participate in this study.

The study will enroll adult patients with MS who initiated ofatumumab according to the physician's advice and independently of the study. Patients will be followed from initiation of ofatumumab either until (i) 12 months (± 1month) after initiation of ofatumumab (End of Study), or until (ii) discontinuation of treatment with ofatumumab prior to the completion of the 12-month follow-up (early termination); whichever occurs first (end of study or early termination).

Condition
Multiple Sclerosis (MS)
Overall Status
Recruiting
Number of Participants
294
Start Date
Dec 21, 2023
Completion Date
Jul 31, 2026
Gender

All
Age(s)
18 Years - 99 Years (Adult, Older Adult)

# Interventions

Other

### ofatumumab

There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol

# Eligibility Criteria

Inclusion Criteria:

1. Male or female, 18 years of age or older
2. Patient with confirmed MS diagnosis
3. Patient initiating treatment with ofatumumab for the first time
4. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
5. Patient not opposed to participation in this study
6. Patient willing and able to complete patient questionnaires

Exclusion Criteria:

1. Patient treated with ofatumumab in the context of a clinical trial

**France**

**Novartis Investigative Site**

Recruiting

Dax,40107,France

**Novartis Investigative Site**

Recruiting

Nimes,30029,France

**Novartis Investigative Site**

Recruiting

Bordeaux Cedex,33076,France

**Novartis Investigative Site**

Recruiting

Toulouse Cedex 9,31059,France

**Novartis Investigative Site**

Recruiting

Lille,59000,France

**Novartis Investigative Site**

Recruiting

Mulhouse,68100,France

**Novartis Investigative Site**

Recruiting

Reims,51092,France

**Novartis Investigative Site**

Recruiting

La Rochelle,17019,France

**Novartis Investigative Site**

Recruiting

Orsay,91400,France

**Novartis Investigative Site**

Recruiting

Brest,29200,France

**Novartis Investigative Site**

Recruiting

Tours,37044,France

**Novartis Investigative Site**

Recruiting

Mantes La Jolie,78200,France

**Novartis Investigative Site**

Recruiting

Rennes,35043,France

**Novartis Investigative Site**

Recruiting

Valence Cedex 9,26953,France

**Novartis Investigative Site**

Recruiting

La Seyne Sur Mer,83500,France

**Novartis Investigative Site**

Recruiting

Paris Cedex 12,F-75571,France

**Novartis Investigative Site**

Recruiting

Villeurbanne,69100,France

**Novartis Investigative Site**

Recruiting

Cahors,46000,France

**Novartis Investigative Site**

Recruiting

Marseille 01,13001,France

**Novartis Investigative Site**

Recruiting

Saint Maur Des Fosses,94100,France

**Novartis Investigative Site**

Recruiting

Agen 09,47923,France

**Novartis Investigative Site**

Recruiting

Le Bouscat,33110,France

**Novartis Investigative Site**

Recruiting

Paris,75017,France

**Novartis Investigative Site**

Recruiting

Chambery cedex,73011,France

**Novartis Investigative Site**

Recruiting

Mont de Marsan cedex,40024,France

**Novartis Investigative Site**

Recruiting

Saverne,67700,France

**Novartis Investigative Site**

Recruiting

Amiens,80054,France

**Novartis Investigative Site**

Recruiting

Le Coudray,28630,France

**Novartis Investigative Site**

Recruiting

Pointe A Pitre,97159,France

**Novartis Investigative Site**

Recruiting

Compiegne,60200,France

**Novartis Investigative Site**

Recruiting

Montlucon,03100,France

**Novartis Investigative Site**

Recruiting

Angers Cedex 9,49933,France

**Novartis Investigative Site**

Recruiting

Selestat,67600,France

**Novartis Investigative Site**

Recruiting

Lens,62307,France

**Novartis Investigative Site**

Recruiting

Altkirch,68130,France

**Novartis Investigative Site**

Recruiting

Poissy,78303,France

**Novartis Investigative Site**

Recruiting

Contamine Sur Arve,74130,France

**Novartis Investigative Site**

Recruiting

Montpellier,34295,France

**Novartis Investigative Site**

Recruiting

Bethune,62400,France

**Novartis Investigative Site**

Recruiting

Strasbourg,67000,France

**Novartis Investigative Site**

Recruiting

Libourne,33505,France

**Novartis Investigative Site**

Recruiting

Lyon,69275,France

**Novartis Investigative Site**

Recruiting

Pringy,74374,France

## Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

**Novartis Pharmaceuticals**

Phone: +41613241111
Email: novartis.email@novartis.com

---

**Source URL:** *https://prod1.novartis.com/clinicaltrials/study/nct06157086*

**List of links present in page**

1. https://clinicaltrials.gov/ct2/show/NCT06157086
2. #trial-eligibility
3. tel:+41613241111
4. mailto:novartis.email@novartis.com